| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Glycerophospholipids, cephalins do not have a defined pharmacological target as they are phospholipid compounds and biochemical reagents. They are a class of phospholipids that serve as major components of biological membranes. Their primary function in research is as membrane components and as biochemical reagents for studying lipid biology and membrane dynamics.
|
|---|---|
| ln Vitro |
No specific in vitro pharmacological activity data are available for Glycerophospholipids, cephalins as drug candidates. In research settings, the compounds are used as phospholipid standards and membrane components. Their activity is assessed in terms of membrane properties and lipid bilayer formation rather than direct biological activity.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for Glycerophospholipids, cephalins as therapeutic agents. The compounds are used as biochemical reagents and lipid standards. They are not administered to animals for pharmacological evaluation. Their applications are limited to in vitro biochemical research.
|
| Enzyme Assay |
For non-cellular assays, Glycerophospholipids, cephalins are characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compounds have a molecular weight of approximately 792.07. Storage: keep in a cool, dry place protected from light and moisture. The compounds appear as a white to off-white powder.
|
| Cell Assay |
For in vitro cell-based studies, Glycerophospholipids, cephalins may be used as membrane components in cell culture studies or as lipid standards. If handled in a biological laboratory context, standard safety precautions should be taken. The compounds should be stored in a cool, dry place protected from light and moisture.
|
| Animal Protocol |
For in vivo animal studies, Glycerophospholipids, cephalins are not typically administered as test compounds. They are used as biochemical reagents and lipid standards. If used in animal studies for specific research purposes, they would be administered via appropriate routes with suitable formulations.
|
| ADME/Pharmacokinetics |
Glycerophospholipids, cephalins have a molecular weight of approximately 792.07. They appear as a white to off-white powder. Purity: typically ≥80%. Storage: keep in a cool, dry place protected from light and moisture. The compounds are stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Glycerophospholipids, cephalins are for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling these compounds. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported.
|
| References | |
| Additional Infomation |
It has been reported that *Streptomyces roseum*, *Streptomyces sporangiosum*, and *Vitis* all contain phosphatidylethanolamine, and relevant data are available for reference. Cephalosporins are phospholipids, and their polar ethanolamine is linked to diacylglycerols via phosphate ester bonds.
Glycerophospholipids, cephalins (CAS 39382-08-6) are also known as phosphatidylethanolamine or cephalins. They are a class of phospholipid compounds that hydrolyze to glycerol, phosphoric acid, ethanolamine, and fatty acids. No clinical trials or therapeutic approvals exist. |
| Exact Mass |
733.562
|
|---|---|
| CAS # |
39382-08-6
|
| PubChem CID |
5327011
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
751.1±70.0 °C at 760 mmHg
|
| Flash Point |
408.1±35.7 °C
|
| Vapour Pressure |
0.0±5.4 mmHg at 25°C
|
| Index of Refraction |
1.474
|
| LogP |
15.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
19
|
| Complexity |
347
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)C
|
| InChi Key |
CFWRDBDJAOHXSH-SECBINFHSA-N
|
| InChi Code |
InChI=1S/C9H18NO8P/c1-7(11)15-5-9(18-8(2)12)6-17-19(13,14)16-4-3-10/h9H,3-6,10H2,1-2H3,(H,13,14)/t9-/m1/s1
|
| Chemical Name |
[(2R)-2-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
